Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the use of cemiplimab, a drug that helps the immune system target cancer cells by binding to a protein called PD-1, to treat early-stage Cutaneous Squamous Cell Carcinoma CSCC, a type of skin cancer. The study compares the effects of cemiplimab injected directly into the cancer lesion with the standard treatment of surgery. The main goals include assessing side effects and determining how well cemiplimab works compared to surgery. Participants will receive either intralesional injections of cemiplimab or undergo primary surgery, which could involve Mohs surgery or other methods ensuring complete margin assessment. The study design is randomized and parallel, meaning participants are assigned to one of these two groups. Treatments and evaluations occur according to a protocol, with follow-up to monitor response and safety. During the trial, participants will be monitored through various assessments including measuring event-free survival up to three years, evaluating complete response of the target lesion at week 13, and checking for adverse events over three years. Measurements of surgical and biopsy defect sizes will also be recorded. The study involves regular visits and follow-up evaluations to track treatment effects and safety throughout participation, which lasts up to the study completion date in 2030.